Stock Alert: Catalent Shares Up Over 3% On Upbeat Q4

(RTTNews) - Shares of Catalent Inc. (CTLT), which have been trading in the range of $31.04 - $91.95 for the past one year, are trading closer to its 52-week high of $91.95. CTLT is currently trading at $90.51, up $2.85 or 3.26% in regular trading session.

The company reported fourth-quarter net income of $134.8 million or $0.85 per share compared to $65.7 million or $0.44 per share last year.

Fourth-quarter adjusted net income was $154.4 million or $0.90 per share compared to $102.9 million or $0.70 per share reported a year ago.

Fourth quarter 2020 net revenue of $947.6 million increased 31% as reported, or 32% in constant currency, from the $725.7 million reported for the fourth quarter a year ago, partially driven by the acquisitions of the cell and gene therapy businesses as well as the acquisition of Bristol-Myers Squibb's biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy, and was partially offset by the divestiture of a manufacturing facility located in Braeside, Australia.

Analysts polled by Thomson Reuters expected earnings of $0.79 per share on revenue of $895.51 million for the quarter. Analysts' estimate typically exclude certain special items.

For fiscal 2021, the company expects adjusted net income in the range of $390 million - $435 million, representing year-on-year growth of 11% - 24%; and net revenue in the range of $3.45 billion - $3.60 billion, representing year-on-year growth of 12% - 16%.

Twelve Wall Street analysts have a consensus revenue estimate of $3.36 billion for fiscal 2021.